The Northstar Note - Fall 2025 Issue

Dec 1, 2025

Fall 2025 Edition | Q4 Update

October was dedicated to advancing clarity in breast cancer care, and the discussions it sparked continue to matter well beyond the month itself. As one of the most nuanced and prevalent cancers, breast cancer highlights the ongoing need for more precision in diagnostics, from treatment selection through monitoring. In this Fall edition, we’re recapping the clinical tools, data spotlights, and educational resources we highlighted throughout October—all designed to support more confident decision-making for breast cancer care teams and their patients.

‍

Clarity in Breast Cancer: October’s Clinical Focus

Last month, we published a series of resources to help clinicians determine which molecular test to use when, how liquid biopsy performs across different subtypes, and how to interpret emerging signals like Tumor Methylation Score in everyday practice.

‍

October’s featured content included:

A practical overview of how to apply liquid biopsy across HR+, HER2+, and TNBC
Guidance on how to use Northstar Select® and Response® together
A real-world case study on detecting progression when imaging leaves open questions

Whether you’re evaluating test timing, selecting the right assay, or interested in incorporating epigenomics into your monitoring method, these resources set the stage for the educational themes we’ll continue building on throughout this quarter.

‍

New Peer-Reviewed Study: Why Sensitivity Matters

We also published a new clinical validation study in the Journal of Liquid Biopsy that reinforces a key point: ultra-high sensitivity directly impacts clinical decision making. In a head-to-head study, Northstar Select® detected 50% more variants than other liquid biopsy assays, enabling more potential treatment opportunities for patients who might otherwise be missed.

You can review the full study here.

Webinar Recap: Find What Others Miss With Northstar Select®

Our recent educational webinar explored how single-molecule precision is helping address longstanding challenges in liquid biopsy for oncology. Featuring peer-reviewed data from a new head-to-head study in the Journal of Liquid Biopsy, the session reviewed how Northstar Select® outperformed other commercially available assays and uncovered more treatment opportunities for late-stage cancer patients.

The discussion also highlighted how tissue-free, methylation-based response monitoring with Northstar Response® provides real-time insight into treatment effectiveness, offering clinicians a clearer view of disease dynamics between imaging intervals.

What We Covered

A walkthrough of the head-to-head validation data showing how Northstar Select outperforms other liquid biopsy tests
How single-molecule precision improves sensitivity and enables precise molecular quantification for treatment response monitoring
Real-world case examples demonstrating how clinicians are using Northstar Select® and Northstar Response® to strengthen treatment planning and patient management

If you missed it, you can watch the full recording here.